INTRODUCTION

Myocardial ischemia reperfusion (I/R) injury occurs due to the reduced blood supply to the myocardium, which further accompanied by the restoration of blood flow. Ischemia in any region of the body can initiate the tissue damage due to lack of oxygen and nutrients; however, the muscles of the heart are more susceptible as they demand more energy for their proper functioning. Therefore, immediate reflow of blood to the ischemic regions can prevent the further damage [1].

Ischemia accompanied by reperfusion can result into reversible or irreversible myocardial injury; however, it also depends on its duration as well as on severity [2]. If reperfusion does not occur, then ischemia leads to cell death. Therefore, reperfusion is the only treatment to save the myocardial cell from the expected death [3]. Delivery of O₂ and substrate for aerobic adenosine triphosphate generation are restored through prompt reperfusion, reperfusion after long duration itself appears to have detrimental consequences [4]. During reperfusion of ischemic tissue, the production of a number of toxic reactive oxygen species (ROS) occurs [5]. ROS may induce tissue injury through lipid peroxidation, protein oxidation, and also by producing damage to DNA [6,7]. The ROS is scavenged by endogenous antioxidants [8]. I/R injury induces the redox imbalance which makes the tissue more prone to oxidative damage [9].

Nowadays, researchers put more attention to develop or find out the medicine with more antioxidant activity and less side effects [10]. As per the traditional medicine system of China, Japan, and Korea, Angelica gigas Nakai (A. gigas) is used to promote blood flow in the brain and heart [10,11]. The various reported pharmacological activities of A. gigas are antiplatelet aggregation, antiinflammatory activity, antioxidant effects, anticancer, and antibacterial [11,12]. INM-176 is a standardized ethanolic extract of A. gigas Nakai roots belongs to family Umbelliferae. It is pale-yellow powder. The various chemical constituents present in this plant are coumarins, chlorogenic acid, ferulic acid, essential oils, and polyacetylenes [13]. The coumarin includes decursinol, decursin, decursinol angelate, marmesin, and nodakenin [14,15]. As decursin and decursinol angelate are the main constituents of INM-176 have powerful antioxidant activity, so on the basis of its antioxidant properties, the present study has been designed to evaluate the cardioprotective effect of INM-176 in I/R injury.

METHOD

Chemicals

INM-176 was provided by Mr. Jong Hoon Ryu, Professor at Kyung Hee University, Seoul, Republic of Korea, in the pale yellow-colored powdered form. The rest of the chemicals used in the present study were purchased from the Loba Chem Pvt., Ltd., CDH Pvt., Ltd., Molychem, Qualigens fine chemicals, and Himedia laboratories Pvt., Ltd., India.

Animals and approvals

Healthy adult albino Wister rats (250-450 g) were used in the study. The adult albino Wister rats were obtained from NIPER, Mohali. The animals were housed in the group of 5 animals each in clean acrylic cages. The animals were kept for 10 days for acclimatization in the central animal house, before the execution of protocol. The animals were kept under natural day and night cycle with temperature of 21±2°C. They were fed with the commercial pelleted animal feed and water ad libitum. The study design was approved by the Institutional Animal Ethics Committee (IAEC) with approval number (LPU/LSPA/IAEC/CPCSEA/MEETING NO. 1/SEPTEMBER 2015/2016 PROTOCOL NO. 7).

Grouping of animals

Five groups (n=6 per group) of animals were made. Drug was dissolved in physiological salt solution and administered through physiological...
salt solution directly into the heart using Langendorff apparatus. For statistical evaluation, ANOVA one and Turkey test were applied, and p value (p≤0.05) was used.

Group I served as control group. The isolated rat hearts, after 15 minutes of stabilization, were continuously perfused with K-H solution for 120 minutes. Group II served as myocardial injury group, and in this group, after the stabilization of 15 minutes, the hearts were subjected to global ischemia accompanied by reperfusion for 30 and 120 minutes, respectively. Group III, IV, and V served as treatment groups (INM-176 150, 300, and 600 mg/kg, respectively). After stabilization for 15 minutes, the hearts were perfused with K-H solution containing INM-176 (150, 300, and 600 mg/kg) for 20 minutes. Then, rat hearts were subjected to global ischemia accompanied by reperfusion with K-H solution containing INM-176 for 30 and 120 minutes, respectively (Table 1).

Isolated perfused rat heart preparation and assessment of the infarct was performed as mentioned in the study by Bhatti et al. 2008 [16]. Lactate dehydrogenase (LDH) and creatine phosphokinase (CK) were estimated in the samples of coronary effluent using 2, 4-dinitrophenylhydrazine method and Ochei method, respectively [17,18].

RESULTS

Effect of INM-176 on I/R-induced LDH release

Global ischemia accompanied by reperfusion for 30 and 120 minutes significantly increased the level of LDH instantly and 30 minutes after reperfusion when compared with control group. It was found that pre-treatment with INM-176 significantly reduced I/R-induced release of LDH when compared with myocardial injury group (p<0.001). Moreover, 600 mg/kg dose of INM-176 significantly attenuated the level of LDH when compared with 150 mg/kg and 300 mg/kg pre-treatment group (Fig. 1 and Table 2).

Effect of INM-176 on I/R-induced CK release

It was found that pre-treatment with INM-176 (300 and 600 mg/kg) significantly reduced the release of CK due to I/R when compared with the myocardial injury group (p<0.001). However, pre-treatment with 150 mg/kg was not statistically significant when compared with the myocardial injury group (p<0.05). Moreover, a dose of 600 mg/kg of INM-176 significantly attenuated the level of CK when compared with 300 mg/kg pre-treatment group (Fig. 2 and Table 3).

Effect of INM-176 on I/R-induced myocardial infarction (MI) size

MI size significantly increased with global ischemia measured by weight and volume method when compared with control group. It was found that pre-treatment with INM-176 (300 and 600 mg/kg) significantly reduced the MI size induced due to I/R when compared with myocardial injury group (p<0.001). However, pre-treatment with 150 mg/kg dose of INM-176 was not statistically significant (p<0.05) when compared with myocardial injury group. Moreover, 600 mg/kg dose of INM-176 significantly attenuated the infarct size when compared with 300 mg/kg pre-treatment group and therefore found to be more effective (Fig. 3 and Table 4).

DISCUSSION

INM-176 is a standardized ethanolic extracts of A. gigas, and chlorogenic acid, ericulin acid, nodakenin, decursinol, decursin, and decursino angelate are its major constituents [10]. The multiple pharmacological activities reported for A. gigas include antibacterial, antiplatelet aggregation, antioxidant, antinematodal, and also antitumor [12]. INM-176 has been reported as neuroprotective agent as it reduces aggregation, antioxidant, antinematodal, and also anticancer [12].

| Groups | Dosing schedule |
|--------|----------------|
| I      | Control        |
| II     | MI             |
| III    | MI+INM 176 (150 mg/kg) |
| IV     | MI+INM 176 (300 mg/kg) |
| V      | MI+INM 176 (600 mg/kg) |

MI: Myocardial infarction

Table 1: Protocol design

Table 2: Effect of INM 176 on I/R-induced LDH release

| Groups | Basal (IU/L) | Immediate reperfusion (IU/L) | After 30 minute of reperfusion (IU/L) |
|--------|--------------|-----------------------------|-------------------------------------|
| I      | 54.25±1.51   | 63.5±0.72                   | 60.27±0.95                          |
| II     | 59.66±0.70   | 405.5±4.33**                | 37.43±5.37**                        |
| III    | 55.5±1.65    | 370.26±7.52^                | 341.9±21^                           |
| IV     | 56.76±2.42   | 339.66±13.81**              | 280.27±8.89**                       |
| V      | 53.5±0.96    | 266.3±5.01*                 | 216.5±7.17**                        |

Values are expressed as mean±SEM. *p<0.001, II versus I, **p<0.001, IV versus II, ***p=0.001, IV and V versus II, ****p<0.001, IV and V versus III, ^p=0.001, V versus IV, SEM: Standard error mean, I/R: Ischemia reperfusion, LDH: Lactate dehydrogenase

Table 3: Effect of INM 176 on I/R-induced CK release

| Groups | Basal (IU/L) | After 5 minutes of reperfusion (IU/L) |
|--------|--------------|--------------------------------------|
| I      | 2.16±0.70    | 24.41±0.46                           |
| II     | 2.37±0.77    | 43.54±1.21**                         |
| III    | 2.30±0.58    | 40.48±0.95                           |
| IV     | 2.36±0.47    | 32.63±5.06                           |
| V      | 2.26±0.49    | 27.79±0.62**                         |

Values are expressed as mean±SEM. *p<0.001, II versus I, **p<0.001, IV versus II, ***p<0.001, IV and V versus II, ****p<0.001, IV and V versus III, ^p<0.005, V versus IV, SEM: Standard error mean, CK: Creatine phosphokinase, I/R: Ischemia reperfusion

Table 4: Effect of INM 176 on I/R-induced infarct size

| Groups | Volume (% age) | Weight (% age) |
|--------|----------------|---------------|
| I      | 13.80±0.65     | 12.46±0.38    |
| II     | 33.95±0.63**   | 29.65±0.77**  |
| III    | 31.03±0.77     | 26.81±1.38    |
| IV     | 23.03±0.85**   | 17.58±1.16**  |
| V      | 18.53±0.62**   | 15.25±0.68**  |

Values are expressed as mean±standard error mean, *p<0.001, II versus I, **p<0.001, IV and V versus II, ***p<0.001, IV and V versus III, ^p<0.05, V versus IV, SEM: Standard error mean, I/R: Ischemia reperfusion

Fig. 1: Effect of INM-176 on ischemia reperfusion-induced lactate dehydrogenase release. Values are expressed as mean±standard error mean. *p<0.001, III versus II, **p<0.001, IV versus II, ***p<0.001, IV and V versus II, ^p<0.001, IV and V versus III, ^^^p<0.001, V versus IV
September Nakai rescues PC12 cells from amyloid ß-protein, against scopolamine-or Aß(1-42)-induced cognitive responsible for myocardial injury [20]. Furthermore, it also represents that the ischemia and reperfusion are the membrane. This further leads to the release of these enzymes. CK and LDH get damaged due to insufficient supply of oxygen, and size was observed in the myocardial injury group as compared to the release. A marked increase in release of LDH and CK as well as infarct peak release, whereas after 5 minutes of reperfusion, CK was at its peak that immediately and after 30 minutes of reperfusion, LDH was at its enzyme has been increased in case of myocardial injury. It was observed that pre-treatment with INM-176 at dose of 300 and 600 mg/kg significantly attenuated the I/R-induced infarct size when compared with the myocardial injury group. However, the reduction in MI size at a dose of 150 mg/kg of INM-176 was not statistically significant when compared with the myocardial injury group. Therefore, in the present study, it has been observed that pre-treatment with INM-176 at a dose of 300 and 600 mg/kg resulted in decrease levels of LDH, CK as well as infarct size when compared with myocardial injury group and 150 mg/kg dose of INM-176. The results were more significant with INM-176 dose of 600 mg/kg, therefore producing greatest effect.

CONCLUSION

On the basis of the findings of this study, it can be concluded that pre-treatment with INM-176 provides cardioprotection against I/R-induced myocardial injury. The effects included reduction in infarct size, reduction in LDH, and CK enzyme and improvement in heart function. Furthermore, it is observed that dose of 600 mg/kg is more effective to reduce the levels of cardiac parameters.

The cardioprotective effect of INM-176 may be associated with its antioxidant activity. Hence, in the future, INM-176 can become the target compound for the development of the dosage form which can be used in the treatment of the I/R-induced injury.

REFERENCES

1. Zhou T, Chuang CC, Zuo L. Molecular characterization of reactive oxygen species in myocardial ischemia-reperfusion injury. Biomed Res Int 2015;2015:1-9.
2. Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: A double edged sword in ischemia/reperfusion versus preconditioning. Redox Biol 2014;2:702-14.
3. Amani M, Jeddi S, Ahmadiani N, Usefzade N, Zaman J. Effect of HEMADO on level of CK-MB and LDH enzymes after ischemia/reperfusion injury in isolated rat heart. Biomics 2013;3(2):101-4.
4. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012;298:229-317.
5. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation-the two keystones of ischemia/reperfusion injury. Int J Cardiol 2002;86(1):41-59.
6. Eltzschig HK, Collard CD. Vascular ischemia and reperfusion injury. Br Med Bull 2004;70:71-86.
7. Hazra B, Biswas S, Mandal N. Antioxidant and free radical scavenging activity of Spondias pinnata. BMC Complement Altern Med 2008;8:63.
8. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001;21(1):2-14.
9. Hou X, Han J, Yuan C, Ren H, Zhang Y, Zhang T, et al. Cardioprotective effects of total flavonoids extracted from xinjiang sprig Rosa rugosa against acute ischemia/reperfusion-induced myocardial injury in isolated rat heart. Cardiovasc Toxicol 2015;16:54-66.
10. Park SJ, Jung HJ, Son MS, Jung JM, Kim DH, Jung IH, et al. Neuroprotective effects of INM-176 against lipopolysaccharide-induced neuronal injury. Pharmacol Biochem Behav 2012;101(3):427-33.
11. Park SJ, Jung JM, Lee HE, Lee YW, Kim DH, Kim JM, et al. The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine-or Aβ(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol 2012;143(2):611-20.
12. Li L, Du JK, Zou LY, Wu T, Lee YW, Kim YH. Decursin Isolated from Angelica gigosa Nakai rescues PC12 cells from amyloid ß-protein-induced neurotoxicity through Nrf2-mediated upregulation of heme.
oxygenase-1: Potential roles of MAPK. Evid Based Complement Alternat Med 2013;2013:467245.

13. Cho JH, Kwon JE, Cho Y, Kim I, Kang SC. Anti-inflammatory effect of Angelica gigas via heme oxygenase (HO)-1 expression. Nutrients 2015;7(6):4862-74.

14. Ma YF, Jung JY, Jung YJ, Choi JH, Jeong WS, Song YS, et al. Anti-inflammatory activities of coumarins isolated from Angelica gigas Nakai on LPS-stimulated RAW 2647 Cells. J Food Sci Nutr 2009;14:179-87.

15. Kang SY, Kim YC. Neuroprotective coumarins from the root of Angelica gigas: Structure-activity relationships. Arch Pharm Res 2007;30(11):1368-73.

16. Bhatti R, Singh K, Ishar MP, Singh J. The effect of Allium sativum on ischemic preconditioning and ischemia reperfusion induced cardiac injury. Indian J Pharmacol 2008;40(6):261-5.

17. King J. A routine method for the estimation of lactic dehydrogenase activity. J Med Lab Technol 1959;16:265-72.

18. Ochei J, Kolhatkar A. Medical Laboratory Science-Theory and Practice. India: McGraw Hills; 2006. p. 168-70.

19. Lee S, Lee YS, Jung SH, Shin KH, Kim BK, Kang SS. Antioxidant activities of the decursinol angelate and decursin from Angelica gigas roots. Nat Prod Sci 2003;9(7):170-3.

20. Somashekar B, Rai SS, Gowda KP. Cardioprotective effects of ethanolic leaf extract of Ipomoea batatas on doxorubicin induced cardiotoxicity in rats. Asian J Pharm Clin Res 2015;8(2):444-50.